TROP2-targeted NK cells for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new type of cell therapy using your own immune cells (NK cells) that are specially engineered to attack cancer cells that have a protein called TROP2. It is for people with advanced solid tumors that have not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have an advanced solid tumor that has not responded to standard treatments, or for which no standard treatment exists.
- Your tumor must show moderate to high levels of a protein called TROP2 (a test on your tumor sample will check this).
- You must be able to do most of your daily activities (ECOG performance status 0 or 1).
- You must have adequate organ function (kidney, liver, heart, and lungs) as determined by blood and other tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new type of immune cell therapy combined with radiation for advanced head and neck cancer. The cells are engineered to target the TROP2 marker on cancer cells and are given after a short course of radiation to help them work better.
This trial tests a new treatment that combines a type of immune cell called NK cells with a targeted drug called T-Dxd for people with advanced breast cancer that has stopped responding to other treatments. The goal is to see if this combination can shrink tumors and help patients live longer.
This early-phase study tests an experimental cell therapy for people with oral precancerous lesions. The therapy uses immune cells engineered to target and destroy abnormal cells in the mouth, potentially preventing them from becoming cancer.
This trial tests an investigational cell therapy called Trop2 CAR-NK for people with advanced non-small cell lung cancer that has come back after standard treatments. The therapy uses your own immune cells (natural killer cells) that are specially trained to find and attack cancer cells that carry the Trop2 protein. This may help shrink tumors or slow the cancer's growth.
This early-phase study tests an antibody-drug (an ADC) that targets TROP2, given by itself and together with an anti–PD-1 medicine. It’s for people with advanced solid cancers that have not responded to standard treatments, aiming to shrink tumors and improve control of the disease.
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.